Liposomes, encapsulation and delivery claims
Words such as liposomal, nano and encapsulated describe technologies, not guaranteed results. Learn what a delivery-system study must demonstrate before a consumer can rely on the claim.
Know the object before believing the label
A liposome is typically a vesicle built from lipid bilayers with an aqueous compartment. Encapsulation can be designed to protect ingredients, modify release or change interactions with skin. The public-domain structural drawing illustrates the general principle; it does not show a SESH formula or prove any specific product contains intact liposomes.
Liposomes, encapsulation and delivery claims — a published visual reference for the topic, not SESH product-test data.
Open full-size image ↗Four separate evidence questions
First: was the carrier characterised (size, stability, composition)? Second: was encapsulation verified in the finished formula? Third: was release or penetration compared against a sensible control? Fourth: did a meaningful human outcome improve with acceptable tolerance? Skipping directly from 'nano' to 'works better' jumps over the entire evidence chain.
Enhanced delivery may change risk too
A system that increases delivery of an active might change irritation or systemic exposure. The preferred outcome depends on what layer is intended and which adverse effects were observed. 'More penetration' is not universally better, particularly when the barrier is compromised or users combine strong products.
A claim-check template
When a brand shows a glossy cross-sectional animation, identify whether it is an illustration or a measurement from the actual product. Ask to see methods, comparator, sample size, duration and clinical outcome. A delivery diagram is useful education only when labelled honestly as a concept.
A liposome is a vesicle with a lipid bilayer and an aqueous core. Naming a delivery system does not by itself prove delivery or efficacy.
Open full-size image ↗Applied decision lab
Serum A is labelled 'nano-liposomal' and publishes a particle image; Serum B reports a controlled trial showing improvement in an agreed skin endpoint. Which is stronger evidence for the benefit claimed?
Evidence-bounded conclusion
Particle characterisation may support a delivery-technology claim. A valid human trial is more directly relevant to an outcome claim; it still needs appraisal. Without a head-to-head trial you cannot declare universal product superiority.
Scientific references
Related SESH learning
For learning only, not evidence of product superiority or medical treatment.
Education only, not a diagnosis or prescription.
